According to the Zhitong Finance APP, CHENGDA PHARMA (301201.SZ) disclosed its performance forecast for 2024. The company expects a net loss attributable to shareholders of the listed company in the range of 21 million to 29 million yuan for the reporting period, with a net loss of 50 million to 60 million yuan after deducting non-recurring gains and losses, marking a shift from profit to loss year-on-year.

The operating revenue for the reporting period is expected to decline by approximately 16% to 27% year-on-year. Among them, the sales revenue from the raw material drug business is expected to decrease by about 33% year-on-year, mainly due to the oversupply of pharmaceutical-grade L-carnitine by customers in 2023, leading to a decline in demand during the reporting period; the company's CDMO business has seen a reduction in orders and a decline in sales revenue. In addition, the company's R&D expenses are expected to be around 90 million to 98 million yuan, an increase of approximately 66 million yuan compared to the previous year. It is estimated that the impact of non-recurring gains and losses on the company's net profit for the reporting period will be about 30 million yuan, mainly from government subsidies and cash management investment income recognized in the current period